{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:31:51Z","timestamp":1787963511704,"version":"build-2784847793"},"reference-count":135,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.berh.2026.102127","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:43:45Z","timestamp":1774021425000},"page":"102127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A practical clinical approach to the diagnosis and management of morphea (localized scleroderma)"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-0569","authenticated-orcid":false,"given":"Caterina","family":"Matucci-Cerinic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lipsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Malattia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2026.102127_bib1","first-page":"605","article-title":"S2k guideline: diagnosis and therapy of localized scleroderma","volume":"22","author":"Kreuter","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.berh.2026.102127_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/archdermatol.2011.305","article-title":"High frequency of genital lichen sclerosus in a prospective series of 76 patients with morphea: toward a better understanding of the spectrum of morphea","volume":"148","author":"Lutz","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4065\/70.11.1068","article-title":"Classification of morphea (localized scleroderma)","volume":"70","author":"Peterson","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2026.102127_bib4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib5","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.5809","article-title":"An evaluation of the performance of current morphea subtype classifications","volume":"157","author":"Prasad","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib7","first-page":"73","article-title":"The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993","volume":"24","author":"Peterson","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/1346-8138.17684","article-title":"Nationwide epidemiological and clinical survey of juvenile-onset morphea in Japan","volume":"52","author":"Hamaguchi","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/acr.20070","article-title":"Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland","volume":"62","author":"Herrick","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102127_bib10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamadermatol.2013.4207","article-title":"Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea","volume":"149","author":"Dharamsi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jpeds.2006.04.052","article-title":"Congenital localized scleroderma","volume":"149","author":"Zulian","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.berh.2026.102127_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","article-title":"Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases","volume":"145","author":"Leitenberger","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","article-title":"Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study","volume":"45","author":"Zulian","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib14","unstructured":"Bolognia J, Schaffer J, Cerroni L. Dermatology. fourth ed.. Elsevier; n.d."},{"key":"10.1016\/j.berh.2026.102127_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1108623","article-title":"Morphea: the 2023 update","volume":"10","author":"Papara","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.berh.2026.102127_bib16","first-page":"203","article-title":"Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea","volume":"190","author":"Kencka","year":"1995","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2026.102127_bib17","article-title":"Keloidal scleroderma: case report and review","volume":"2015","author":"Kassira","year":"2015","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.berh.2026.102127_bib18","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jaad.2020.07.109","article-title":"Isomorphic and symmetric adult-onset generalized morphea are associated with distinctive clinical features: a retrospective multicenter study","volume":"84","author":"Braud","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1365-2133.2001.04041.x","article-title":"Squamous cell carcinoma arising in a patient with long-standing pansclerotic morphea","volume":"144","author":"Parodi","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1525-1470.2002.00033.x","article-title":"Squamous cell carcinoma in pansclerotic morphea of childhood","volume":"19","author":"Wollina","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib21","doi-asserted-by":"crossref","first-page":"P77","DOI":"10.1186\/1546-0096-9-S1-P77","article-title":"Autologous stem cell transplantation in two children with disabling pansclerotic morphea","volume":"9","author":"Moll","year":"2011","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.berh.2026.102127_bib22","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2202318","article-title":"Variant STAT4 and response to ruxolitinib in an autoinflammatory syndrome","volume":"388","author":"Baghdassarian","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102127_bib23","unstructured":"Paller AS, Mancini AJ. Hurwitz clinical pediatric dermatology. sixth ed.; n.d."},{"key":"10.1016\/j.berh.2026.102127_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.annder.2022.11.003","article-title":"Early morphea appearing as a port-wine stain: a clinical challenge","volume":"150","author":"Matucci-Cerinic","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib25","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/pde.12722","article-title":"Linear Morphea mimicking Lichen Striatus in its early presentation","volume":"33","author":"Mu\u00f1oz Garza","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1525-1470.2000.01757.x","article-title":"Bilateral en coup de sabre-a rare entity","volume":"17","author":"Rai","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0009922810396546","article-title":"Presentations and treatment of childhood scleroderma: localized scleroderma, eosinophilic fasciitis, systemic sclerosis, and graft-versus-host disease","volume":"50","author":"Hedrich","year":"2011","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.berh.2026.102127_bib28","first-page":"381","article-title":"Eosinophilic fasciitis--progression to linear scleroderma: a case report","volume":"41","author":"Balat","year":"1999","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.berh.2026.102127_bib29","article-title":"Eosinophilic fasciitis in children frequently progresses to scleroderma-like cutaneous fibrosis","volume":"20","author":"Farrington","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib30","first-page":"527","article-title":"Juvenile eosinophilic fasciitis: three case reports with review of the literature","volume":"34","author":"Papa","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib31","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3389\/fimmu.2019.01487","article-title":"Autoantibodies in morphea: an update","volume":"10","author":"Khatri","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102127_bib32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamadermatol.2013.4207","article-title":"Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea","volume":"149","author":"Dharamsi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib33","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.3899\/jrheum.080098","article-title":"Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study","volume":"35","author":"Arkachaisri","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaad.2012.04.003","article-title":"Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center","volume":"67","author":"Kreuter","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5114\/pdia.2014.40978","article-title":"Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome","volume":"31","author":"Lis-\u015awi\u0119ty","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.berh.2026.102127_bib36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/ard.62.8.771","article-title":"Antiphospholipid antibody in localised scleroderma","volume":"62","author":"Sato","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102127_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2230.2005.01776.x","article-title":"Rheumatoid factor isotypes in localized scleroderma","volume":"30","author":"Mimura","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib38","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/art.21264","article-title":"Localized scleroderma in childhood is not just a skin disease","volume":"52","author":"Zulian","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102127_bib39","series-title":"Eular textbook on paediatric rheumatology","author":"Martini","year":"2018"},{"key":"10.1016\/j.berh.2026.102127_bib40","first-page":"171","article-title":"Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases","volume":"13","author":"Marzano","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103812","article-title":"The burden of extracutaneous manifestations in juvenile localized scleroderma: a literature review","volume":"24","author":"Liguoro","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102127_bib42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2340\/00015555-3238","article-title":"Acquired Strabismus in linear Scleroderma of the face","volume":"99","author":"Martini","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib43","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/bjo.2007.116038","article-title":"Ocular involvement in children with localised scleroderma: a multi-centre study","volume":"91","author":"Zannin","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.berh.2026.102127_bib44","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1016\/j.acra.2025.02.030","article-title":"Neuroimaging and clinical features of parry-romberg syndrome and Linear Morphea en-coup-de-sabre in a large case series","volume":"32","author":"Gorolay","year":"2025","journal-title":"Acad Radiol"},{"key":"10.1016\/j.berh.2026.102127_bib45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.1989.tb01350.x","article-title":"An investigation into the incidence of auto-immune disorders in patients with localized morphoea","volume":"120","author":"Harrington","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102127_bib47","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3899\/jrheum.081284","article-title":"The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures","volume":"36","author":"Arkachaisri","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","article-title":"Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study","volume":"49","author":"Arkachaisri","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jaad.2013.02.007","article-title":"The Localized Scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population","volume":"69","author":"Kelsey","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12969-018-0254-9","article-title":"Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile localized scleroderma","volume":"16","author":"Agazzi","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.berh.2026.102127_bib51","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/acr.25281","article-title":"Capturing the range of disease involvement in localized scleroderma: the localized scleroderma total severity scale","volume":"76","author":"Li","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102127_bib52","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/41.10.1178","article-title":"Juvenile-onset localized scleroderma activity detection by infrared thermography","volume":"41","author":"Martini","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/srt.12619","article-title":"Detecting and quantifying activity\/inflammation in localized scleroderma with thermal imaging","volume":"25","author":"Ranosz-Janicka","year":"2019","journal-title":"Skin Res Technol"},{"key":"10.1016\/j.berh.2026.102127_bib54","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/rheumatology\/keaa392","article-title":"Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma","volume":"60","author":"Martini","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib55","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102127_bib56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484947","article-title":"Dermoscopy of Morphea and cutaneous Lichen sclerosus: clinicopathological correlation Study and comparative analysis","volume":"233","author":"Errichetti","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2026.102127_bib57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/jcm11030764","article-title":"Usefulness of dermoscopy in localized scleroderma (LoS, Morphea) diagnosis and assessment-monocentric cross-sectional Study","volume":"11","author":"Szczepanik-Ku\u0142ak","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.berh.2026.102127_bib58","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/14397595.2013.844301","article-title":"High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma","volume":"24","author":"Porta","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib59","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/jdv.16308","article-title":"Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imaging","volume":"34","author":"Weibel","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/2397198318799244","article-title":"Why, how, and when to use color Doppler ultrasound for improving precision in the diagnosis, assessment of severity and activity in morphea","volume":"4","author":"Wortsman","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2026.102127_bib61","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1684\/ejd.2021.4189","article-title":"Low effectiveness of methotrexate in the management of localised scleroderma (morphea) based on an ultrasound activity score","volume":"31","author":"Vera-Kellet","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib62","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/jum.16247","article-title":"Ultrasound Morphea activity scoring (US-MAS): modified US-MAS","volume":"42","author":"Wortsman","year":"2023","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.berh.2026.102127_bib63","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1007\/s00330-024-10738-z","article-title":"Superb microvascular imaging for evaluating the activity of juvenile localised scleroderma: a preliminary study","volume":"34","author":"Chen","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.berh.2026.102127_bib64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2214\/AJR.07.2163","article-title":"MRI findings in deep and generalized morphea (localized scleroderma)","volume":"190","author":"Horger","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.berh.2026.102127_bib65","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00256-025-04909-2","article-title":"Localized scleroderma: anatomic MRI findings of morphea with inter-reader analysis","volume":"54","author":"Iancau","year":"2025","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.berh.2026.102127_bib66","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/pde.12001","article-title":"A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings","volume":"29","author":"Chiu","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12969-021-00512-6","article-title":"Magnetic resonance imaging findings in children with Parry-Romberg syndrome and en coup de sabre","volume":"19","author":"Knights","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.berh.2026.102127_bib68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/00128071-200910030-00004","article-title":"Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study","volume":"10","author":"Kroft","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib69","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2004.06318.x","article-title":"Localized scleroderma: response to occlusive treatment with tacrolimus ointment","volume":"152","author":"Mancuso","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib70","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1346-8138.2008.00552.x","article-title":"Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study","volume":"35","author":"Stefanaki","year":"2008","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib71","article-title":"Morphea involving the lips and gingiva: a rare case report","volume":"15","author":"Albagieh","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.berh.2026.102127_bib72","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1111\/jdv.18488","article-title":"Successful therapy of ulcerative morphea with topical application of pimecrolimus","volume":"37","author":"Moelleken","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib73","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0190-9622(98)70077-5","article-title":"Topical calcipotriene for morphea\/linear scleroderma","volume":"39","author":"Cunningham","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib74","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1525-1470.2001.018003241.x","article-title":"Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea","volume":"18","author":"Kreuter","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000073093","article-title":"Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method","volume":"207","author":"de Rie","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2026.102127_bib76","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","article-title":"A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","volume":"54","author":"Kreuter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib77","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1365-4632.2010.04843.x","article-title":"Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma","volume":"50","author":"Su","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaad.2013.10.018","article-title":"Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study","volume":"70","author":"Vasquez","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib79","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/1523-1747.ep12522855","article-title":"The carcinogenic effect of UVA irradiation","volume":"81","author":"Staberg","year":"1983","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib80","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archderm.1994.01690050133027","article-title":"Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients","volume":"130","author":"Joly","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib81","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archderm.141.7.847","article-title":"Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma","volume":"141","author":"Kreuter","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib82","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.110210","article-title":"Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study","volume":"39","author":"Torok","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib83","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1365-2133.2006.07497.x","article-title":"Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children","volume":"155","author":"Weibel","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib84","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2012.03.036","article-title":"A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea)","volume":"67","author":"Zulian","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib85","first-page":"609","article-title":"Treatment of pediatric localized scleroderma with methotrexate","volume":"33","author":"Fitch","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib86","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11845-008-0217-0","article-title":"Juvenile localised scleroderma: a retrospective review of response to systemic treatment","volume":"177","author":"Cox","year":"2008","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.berh.2026.102127_bib87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2133.2011.10535.x","article-title":"Relapse after systemic treatment in paediatric morphoea","volume":"166","author":"Mirsky","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-3476(00)90056-8","article-title":"Methotrexate and corticosteroid therapy for pediatric localized scleroderma","volume":"136","author":"Uziel","year":"2000","journal-title":"J Pediatr"},{"key":"10.1016\/j.berh.2026.102127_bib89","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","article-title":"Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib90","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2340\/00015555-2297","article-title":"Use of mycophenolate Mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib91","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamadermatol.2020.0035","article-title":"Evaluation of the effectiveness and tolerability of Mycophenolate Mofetil and mycophenolic acid for the treatment of morphea","volume":"156","author":"Arthur","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib92","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa873","article-title":"Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib93","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia)","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102127_bib94","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/ced.15028","article-title":"Rapid response to abatacept in treatment-resistant pansclerotic morphoea","volume":"47","author":"Attard","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib95","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/00015555-2878","article-title":"Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series","volume":"98","author":"Fage","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib96","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: a pediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102127_bib97","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2340\/00015555-1136","article-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases","volume":"91","author":"Stausb\u00f8l-Gr\u00f8n","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib98","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/2397198320983240","article-title":"A case of recalcitrant Linear Morphea responding to subcutaneous abatacept","volume":"6","author":"Talia","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2026.102127_bib99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2022.09.024","article-title":"Tocilizumab for refractory morphea in adults: a case series","volume":"30","author":"Lonowski","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102127_bib100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib101","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-019-1015-7","article-title":"Linear scleroderma \u201cen coup de sabre\u201d with extensive brain involvement-Clinicopathologic correlations and response to anti-Interleukin-6 therapy","volume":"14","author":"Magro","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 106","key":"10.1016\/j.berh.2026.102127_bib102","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?","volume":"35","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib103","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/2397198320975872","article-title":"Parry Romberg disease with En Coup de Sabre Scleroderma: effect of tocilizumab on periodontal bone inflammation","volume":"6","author":"Meneghetti","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2026.102127_bib104","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.reuma.2018.05.001","article-title":"Scleroderma \u201cen coup de sabre\u201d With Epilepsy and Uveitis Successfully Treated With Tocilizumab","volume":"16","author":"Osminina","year":"2020","journal-title":"Reumatol Cl\u00ednica"},{"key":"10.1016\/j.berh.2026.102127_bib105","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1111\/jdv.19692","article-title":"Tocilizumab for refractory post-COVID-19 pansclerotic morphea","volume":"38","author":"Saraswat","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2026.102127_bib106","doi-asserted-by":"crossref","DOI":"10.1186\/s42358-025-00511-1","article-title":"The efficacy and safety of tocilizumab in juvenile localised scleroderma patients: a retrospective cohort study in Eastern China","author":"Shen","year":"2025","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib107","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of pansclerotic morphea treated with tocilizumab","volume":"155","author":"Zhang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib108","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2025.05.1377","article-title":"Use of the oral Janus kinase inhibitor tofacitinib in the treatment of morphea: a retrospective study","volume":"93","author":"Ansari","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15295","article-title":"Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: a single-center experience","volume":"27","author":"Colussi","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2026.102127_bib110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib","volume":"4","author":"Kim","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102127_bib111","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15942","article-title":"Bullous lichen sclerosus-generalized morphea overlap syndrome improved by tofacitinib","volume":"35","author":"Liu","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.berh.2026.102127_bib112","first-page":"26","article-title":"Efficacy and TOLERABILITY OF JANUS KINASE inhibitor tofacitinib in juvenile linear scleroderma. Case series of 5 patients","author":"Osminina","year":"2025","journal-title":"Georgian Med News"},{"key":"10.1016\/j.berh.2026.102127_bib113","first-page":"469","article-title":"Successful therapy of refractory cutaneous morphea with tofacitinib","volume":"159","author":"Russo","year":"2024","journal-title":"Ital J Dermatol Venerol"},{"key":"10.1016\/j.berh.2026.102127_bib114","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1007\/s10067-020-05118-z","article-title":"Full histological and clinical regression of morphea with tofacitinib","volume":"39","author":"Scheinberg","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib115","first-page":"e424","article-title":"JAK-STAT pathway is involved in cutaneous sclerosis processes: generalized morphea successfully treated with baricitinib","volume":"50","author":"Labrandero Hoyos","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib116","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1346-8138.16980","article-title":"Successful treatment with baricitinib of linear morphea following the lines of Blaschko mimicking lichen striatus","volume":"51","author":"Zou","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib117","article-title":"Janus kinase inhibitors for the treatment of pediatric morphea: a systematic review","author":"Moschella","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib118","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/pde.16025","article-title":"Localized Morphea in a pediatric patient successfully treated with topical ruxolitinib","volume":"42","author":"Rabinowitz","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib119","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/pde.15844","article-title":"Benefits of the topical JAK inhibitor delgocitinib in a patient with pediatric localized scleroderma","volume":"42","author":"Yamamoto","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archdermatol.2010.120","article-title":"Treatment of recalcitrant generalized morphea with infliximab","volume":"146","author":"Diab","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib121","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/18743129014090100030","article-title":"A case report of successful treatment of recalcitrant childhood localized scleroderma with Infliximab and leflunomide","volume":"9","author":"Ferguson","year":"2015","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.berh.2026.102127_bib122","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.55563\/clinexprheumatol\/o1gtvk","article-title":"Unilateral generalised morphea successfully treated with rituximab and mycophenolate mofetil","volume":"39","author":"Quintarelli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2026.102127_bib123","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jdcr.2018.04.016","article-title":"Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: response to rituximab","volume":"4","author":"Traboulsi","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.berh.2026.102127_bib124","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/dth.12248","article-title":"Imatinib treatment of therapy resistant generalized deep morphea","volume":"28","author":"Alc\u00e1ntara-Reifs","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.berh.2026.102127_bib125","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/j.1525-1470.2012.01882.x","article-title":"Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate","volume":"30","author":"Inamo","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib126","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.jaad.2010.02.030","article-title":"Imatinib treatment of generalized localized scleroderma (morphea)","volume":"63","author":"Moinzadeh","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib127","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/pde.14327","article-title":"Imatinib as a potentially effective therapeutic alternative in corticosteroid-resistant eosinophilic fasciitis","volume":"37","author":"Wu","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib128","article-title":"Successful treatment of refractory severe localized scleroderma with anifrolumab","author":"Fayos-Gregori","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib129","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1097\/PRS.0000000000006291","article-title":"Fat grafting for the treatment of scleroderma","volume":"144","author":"Strong","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.berh.2026.102127_bib130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpeds.2021.01.068","article-title":"Morbidity and disability in juvenile localized scleroderma: the case for early recognition and systemic immunosuppressive treatment","volume":"234","author":"Li","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.berh.2026.102127_bib131","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.13514","article-title":"Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease","volume":"172","author":"Mertens","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib132","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archdermatol.2010.239","article-title":"An evaluation of long-term outcomes in adults with pediatric-onset morphea","volume":"146","author":"Saxton-Daniels","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2026.102127_bib133","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1093\/rheumatology\/keab238","article-title":"Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102127_bib134","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology Centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102127_bib135","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.17312","article-title":"Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma","volume":"180","author":"Kurzinski","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:46:26Z","timestamp":1781509586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1521694226000124"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102127","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical clinical approach to the diagnosis and management of morphea (localized scleroderma)","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102127"}}